Category: Health

Is Lantus Insulin Linked to Increased Risk of Cancer? New Study Begins

Recently published studies suggested that insulin glargine (a synthetic insulin preparation marketed under the trade name Lantus), may be associated with a higher risk of certain cancers than other insulins or oral glucose lowering medications. However, these studies were unable to control for important factors such as obesity that may have driven the association...
0 Shares
JDRF New Logo

First Treatment For Diabetic Related Eye Disease May Soon Be Available

According to a JDRF press release great progress has been made towards finding a treatment for diabetes-related eye disease. Novartis Pharmaceuticals, based in Switzerland, announced that the drug Lucentis has been submitted to the European Union's regulatory agency, European Medicines Agency, for approval for the treatment of diabetic macular edema...
0 Shares

EyeSmart EyeCommitted

Diabetic retinopathy is the leading cause of new cases of legal blindness in working-age Americans, and more than half of all people living with diabetes do not get the recommended annual dilated eye exams.
0 Shares

Senate Passes Women’s Health Amendment

The US Senate approved an amendment, put forward by Senator Barbara Mikulski, Democrat of Maryland, that would require insurance companies to offer free mammograms and other preventive services including annual diabetes screening...
0 Shares

Surgery Recognized as Legitimate Treatment for Type 2 Diabetes

A first-of-its-kind consensus statement on diabetes surgery was published online yesterday in the Annals of Surgery. The statement was issued following the first international consensus conference, Diabetes Surgery Summit (DSS), where an international group of more than 50 scientific and medical experts agreed on a set of evidence-based guidelines and definitions that are meant to guide the use...
0 Shares

Exercise Every Other Day

If you are physically able, try your best to make at least fifteen minutes of exercise part of your routine.
0 Shares